French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management: the FRENCH CORONA Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,003
- 试验地点
- 1
- 主要终点
- Mortality at day 28
研究概览
简要总结
Since December 2019, a new agent, the SARS-Cov-2 coronavirus has been rapidly spreading from China to other countries causing an international outbreak of respiratory illnesses named COVID-19. In France, the first cases have been reported at the end of January with more than 60000 cases reported since then. A significant proportion (20-30%) of hospitalized COVID-19 patients will be admitted to intensive care unit. However, few data are available for this special population in France.
We conduct a large observational cohort of ICU suspected or proven COVID-19 patients that will enable to describe the initial management of COVID 19 patients admitted to ICU and to identify factors correlated to clinical outcome.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients admitted to ICU for suspected or proven SARS-Cov-2 infection, defined by positive SARS-Cov-2 PCR or CT scan images
- •Patient > or= 18 years
排除标准
- •Patient study refusal
- •Patient already enrolled in the present study
- •Patient with respiratory illness with negative COVID-19 CT scan images and negative COVID_19 PCR
结局指标
主要结局
Mortality at day 28
时间窗: day 28
Mortality at day 28
次要结局
- Patients receiving mechanical ventilation(up to day 28)
- Vital status(day 28)
- Antiviral therapy(up to day 28)
- severe complications(up to day 28)
- Delay in Microbiological diagnosis(day 1)
- Imaging(day 1)
- Antibiotic therapy(day 28)
- Covid-19 treatments(up to day 28)
- Patients receiving renal replacement therapy(up to day 28)